JP2006517567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517567A5 JP2006517567A5 JP2006502017A JP2006502017A JP2006517567A5 JP 2006517567 A5 JP2006517567 A5 JP 2006517567A5 JP 2006502017 A JP2006502017 A JP 2006502017A JP 2006502017 A JP2006502017 A JP 2006502017A JP 2006517567 A5 JP2006517567 A5 JP 2006517567A5
- Authority
- JP
- Japan
- Prior art keywords
- aza
- bicyclo
- octane
- disorder
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000019906 panic disease Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000017194 Affective disease Diseases 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 206010043269 Tension headache Diseases 0.000 claims description 4
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 230000036651 mood Effects 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000024714 major depressive disease Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000008811 Agoraphobia Diseases 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 241000208125 Nicotiana Species 0.000 claims description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 claims description 2
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010034912 Phobia Diseases 0.000 claims description 2
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010052276 Pseudodementia Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 208000025748 atypical depressive disease Diseases 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 208000022257 bipolar II disease Diseases 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000006145 cocaine dependence Diseases 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 210000001097 facial muscle Anatomy 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000000938 luteal effect Effects 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 230000007074 memory dysfunction Effects 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 230000003961 neuronal insult Effects 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 206010036596 premature ejaculation Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 201000001716 specific phobia Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- -1 2,3-dichlorophenoxymethyl Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- OUTREUMPVYZFKZ-VIHIWDAPSA-N (3r,4s)-3-(3-chlorophenyl)-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@@H]1C2CCC(C[C@H]1C=1C=C(Cl)C=CC=1)N2C)OC1=CC=CC(Cl)=C1Cl OUTREUMPVYZFKZ-VIHIWDAPSA-N 0.000 claims 1
- DNDIRUNOUOMZBH-CNHJLYCKSA-N (3r,4s)-3-(3-chlorophenyl)-8-methyl-4-(naphthalen-1-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound C1([C@H]2[C@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)=CC=CC(Cl)=C1 DNDIRUNOUOMZBH-CNHJLYCKSA-N 0.000 claims 1
- OUTREUMPVYZFKZ-VZDIDWBNSA-N (3s,4r)-3-(3-chlorophenyl)-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C=1C=C(Cl)C=CC=1)N2C)OC1=CC=CC(Cl)=C1Cl OUTREUMPVYZFKZ-VZDIDWBNSA-N 0.000 claims 1
- CGQKKDKUPUHQQG-VZDIDWBNSA-N (3s,4r)-3-(3-chlorophenyl)-4-[(2,3-difluorophenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C=1C=C(Cl)C=CC=1)N2C)OC1=CC=CC(F)=C1F CGQKKDKUPUHQQG-VZDIDWBNSA-N 0.000 claims 1
- FWCHGXSOLMAOCD-WBFXSEPVSA-N (3s,4r)-3-(3-chlorophenyl)-4-[(2,3-dimethoxyphenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound COC1=CC=CC(OC[C@@H]2[C@H](CC3CCC2N3C)C=2C=C(Cl)C=CC=2)=C1OC FWCHGXSOLMAOCD-WBFXSEPVSA-N 0.000 claims 1
- DNDIRUNOUOMZBH-LQBIAYRMSA-N (3s,4r)-3-(3-chlorophenyl)-8-methyl-4-(naphthalen-1-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)=CC=CC(Cl)=C1 DNDIRUNOUOMZBH-LQBIAYRMSA-N 0.000 claims 1
- MKTXIVUGJMMDPT-UJEKJILKSA-N (3s,4r)-3-butyl-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(N2C)C[C@@H]1CCCC)OC1=CC=CC(Cl)=C1Cl MKTXIVUGJMMDPT-UJEKJILKSA-N 0.000 claims 1
- MIFKAKHTONPRMG-UJEKJILKSA-N (3s,4r)-3-butyl-4-[(2,3-dichlorophenyl)sulfanylmethyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(N2C)C[C@@H]1CCCC)SC1=CC=CC(Cl)=C1Cl MIFKAKHTONPRMG-UJEKJILKSA-N 0.000 claims 1
- DYDDLCLIKCENRH-FFKUYJCKSA-N (3s,4r)-3-butyl-8-methyl-4-(naphthalen-1-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound C1=CC=C2C(OC[C@H]3C4CCC(N4C)C[C@@H]3CCCC)=CC=CC2=C1 DYDDLCLIKCENRH-FFKUYJCKSA-N 0.000 claims 1
- DAQHJYNGLVDBGR-IOSBVQAASA-N (3s,4r)-3-cyclopropyl-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@H]1C1CC1)N2C)OC1=CC=CC(Cl)=C1Cl DAQHJYNGLVDBGR-IOSBVQAASA-N 0.000 claims 1
- STIZVEYLFRFRSD-VZDIDWBNSA-N (3s,4r)-4-[(2,3-dichlorophenoxy)methyl]-3-(3-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C=1C=C(F)C=CC=1)N2C)OC1=CC=CC(Cl)=C1Cl STIZVEYLFRFRSD-VZDIDWBNSA-N 0.000 claims 1
- JLLIPUGDCXAUEP-OYNVLQORSA-N (3s,4r)-4-[(2,3-dichlorophenoxy)methyl]-3-ethyl-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(N2C)C[C@@H]1CC)OC1=CC=CC(Cl)=C1Cl JLLIPUGDCXAUEP-OYNVLQORSA-N 0.000 claims 1
- SMCCFJLGYWDNNQ-IOSBVQAASA-N (3s,4r)-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-3-propan-2-yl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(N2C)C[C@H]1C(C)C)OC1=CC=CC(Cl)=C1Cl SMCCFJLGYWDNNQ-IOSBVQAASA-N 0.000 claims 1
- BWYCGNAZYLFYDG-VZDIDWBNSA-N (3s,4r)-4-[(2-chloro-3-fluorophenoxy)methyl]-3-(3-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C=1C=C(Cl)C=CC=1)N2C)OC1=CC=CC(F)=C1Cl BWYCGNAZYLFYDG-VZDIDWBNSA-N 0.000 claims 1
- WBSMPPDAPDGBGN-ZBOXLXRLSA-N (4r)-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(CC1)N2C)OC1=CC=CC(Cl)=C1Cl WBSMPPDAPDGBGN-ZBOXLXRLSA-N 0.000 claims 1
- XTLYISOCIGFLLM-HJOIGYKYSA-N (4r)-8-methyl-4-(naphthalen-1-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound C1=CC=C2C(OC[C@H]3C4CCC(CC3)N4C)=CC=CC2=C1 XTLYISOCIGFLLM-HJOIGYKYSA-N 0.000 claims 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical class C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 230000001561 neurotransmitter reuptake Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 206010046494 urge incontinence Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010040981 Sleep attacks Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300212 | 2003-02-12 | ||
| US44810703P | 2003-02-20 | 2003-02-20 | |
| PCT/EP2004/050106 WO2004072075A1 (en) | 2003-02-12 | 2004-02-10 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517567A JP2006517567A (ja) | 2006-07-27 |
| JP2006517567A5 true JP2006517567A5 (enExample) | 2011-01-20 |
Family
ID=32870666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502017A Ceased JP2006517567A (ja) | 2003-02-12 | 2004-02-10 | 新規８−アザ−ビシクロ［３．２．１］オクタン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7250425B2 (enExample) |
| EP (1) | EP1594874A1 (enExample) |
| JP (1) | JP2006517567A (enExample) |
| AU (1) | AU2004212165B2 (enExample) |
| CA (1) | CA2515732A1 (enExample) |
| MX (1) | MXPA05008315A (enExample) |
| NZ (1) | NZ541248A (enExample) |
| WO (1) | WO2004072075A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040235906A1 (en) * | 2001-08-08 | 2004-11-25 | Gouliaev Alex Haahr | Substituted amine derivatives and their use as monoamine neurotransmitter re-up-take inhibitors |
| DK1675591T3 (da) * | 2003-10-16 | 2011-11-14 | Neurosearch As | Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer |
| AU2005205882A1 (en) * | 2004-01-22 | 2005-08-04 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist |
| EP1727547A1 (en) * | 2004-01-22 | 2006-12-06 | Neurosearch A/S | Compounds for the sustained reduction of body weight |
| JP2008501656A (ja) * | 2004-06-04 | 2008-01-24 | ノイロサーチ アクティーゼルスカブ | β−アミロイド（Ａβ４０及びＡβ４２）生成阻害のためのモノアミン神経伝達物質再取り込み阻害剤 |
| EP1779851A1 (en) * | 2005-10-31 | 2007-05-02 | Boehringer Ingelheim Pharma GmbH & Co.KG | Treatment of diabetes |
| WO2009135678A2 (en) * | 2008-05-08 | 2009-11-12 | Detrey Gmbh Dentsply | Radical polymerisation inhibitors for light-curable dental materials |
| KR102662065B1 (ko) | 2017-02-17 | 2024-05-07 | 트레베나, 인코포레이티드. | 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법 |
| WO2018152293A1 (en) | 2017-02-17 | 2018-08-23 | Trevena, Inc. | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554626A (en) | 1992-12-23 | 1996-09-10 | Neurosearch A/S | Substituted heterocyclic compounds as dopamine-reuptake inhibitors |
| AU672052B2 (en) | 1992-12-23 | 1996-09-19 | Neurosearch A/S | Antidepressant and antiparkinsonian compounds |
| RU2162469C2 (ru) | 1995-11-02 | 2001-01-27 | Ньюросерч А/С | Конденсированные тропановые производные в качестве ингибиторов обратного захвата нейромедиаторов |
| BR9707636A (pt) | 1996-02-22 | 1999-07-27 | Neurosearch As | Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo |
| WO2002076440A2 (en) * | 2001-03-23 | 2002-10-03 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease with piperidin derivates |
| US20040106643A1 (en) * | 2001-05-23 | 2004-06-03 | Gouliaev Alex Haarh | Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US20040235906A1 (en) | 2001-08-08 | 2004-11-25 | Gouliaev Alex Haahr | Substituted amine derivatives and their use as monoamine neurotransmitter re-up-take inhibitors |
| US7381733B2 (en) * | 2001-11-30 | 2008-06-03 | Neurosearch A/S | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases |
-
2004
- 2004-02-10 MX MXPA05008315A patent/MXPA05008315A/es active IP Right Grant
- 2004-02-10 US US10/543,828 patent/US7250425B2/en not_active Expired - Fee Related
- 2004-02-10 EP EP04709632A patent/EP1594874A1/en not_active Withdrawn
- 2004-02-10 AU AU2004212165A patent/AU2004212165B2/en not_active Ceased
- 2004-02-10 CA CA002515732A patent/CA2515732A1/en not_active Abandoned
- 2004-02-10 NZ NZ541248A patent/NZ541248A/en not_active IP Right Cessation
- 2004-02-10 JP JP2006502017A patent/JP2006517567A/ja not_active Ceased
- 2004-02-10 WO PCT/EP2004/050106 patent/WO2004072075A1/en not_active Ceased